Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 72, Issue 2

Evaluation of the ID NOW among symptomatic individuals during the Omicron wave Open Access

Abstract

Starting in December, 2020, the ID NOW was implemented throughout the province of Alberta, Canada (population 4.4 million) in various settings.

ID NOW’s test performance with SARS-CoV-2 Omicron variant BA.1 is unknown.

To assess the ID NOW performance among symptomatic individuals during the BA.1 Omicron wave and compare it to previous SARS-CoV-2 variant waves.

The ID NOW was assessed in two locations among symptomatic individuals: rural hospitals and community assessment centres (AC) during the period 5–18 January 2022. Starting 5 January, Omicron represented >95 % of variants detected in our population. For every individual tested, two swabs were collected: one for ID NOW testing and the other for either reverse-transcriptase polymerase chain reaction (RT-PCR) confirmation of negative ID NOW results or for variant testing of positive ID NOW results.

A total of 3041 paired samples were analysed (1139 RT-PCR positive). From this, 1873 samples were from 42 COVID-19 AC and 1168 from 69 rural hospitals. ID NOW sensitivity for symptomatic individuals presenting to community AC and rural hospitals was 96.0 % [95 % confidence interval (CI) 94.5–97.3 %, =830 RT-PCR positive], and 91.6 % (95 % CI 87.9–94.4 %, =309 RT-PCR positive), respectively. SARS-CoV-2 positivity rate was very high for both populations (44.3 % at AC, 26.5 % in hospital).

Sensitivity of ID NOW SARS-CoV-2, compared to RT-PCR, is very high during the BA.1 Omicron wave, and is significantly higher when compared to previous SARS-CoV-2 variant waves.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): COVID-19 , ID NOW , POCT , rapid diagnostics , SARS-CoV-2 and symptomatic
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001669
2023-02-27
2025-01-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/72/2/jmm001669.html?itemId=/content/journal/jmm/10.1099/jmm.0.001669&mimeType=html&fmt=ahah

References

  1. United States Food and Drug Administration ID NOW COVID-19 – instructions for use; 2020 https://www.fda.gov/media/136525/download accessed 10 February 2022
  2. Stokes W, Venner AA, Buss E, Tipples G, Berenger BM. Prospective population-level validation of the Abbott ID NOW severe acute respiratory syndrome coronavirus 2 device implemented in multiple settings for testing asymptomatic and symptomatic individuals. Clin Microbiol Infect 2023; 29:247–252 [View Article]
     [Google Scholar]
  3. Abbott Evaluating Omicron and other COVID variants to ensure test effectiveness; 2021 https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html accessed 27 February 2022
  4. Government of Alberta COVID-19 Alberta statistics; 2022 https://www.alberta.ca/stats/covid-19-alberta-statistics.htm accessed 27 February 2022
  5. Zhao H, Lu L, Peng Z, Chen L-L, Meng X et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect 2022; 11:277–283 [View Article] [PubMed]
     [Google Scholar]
  6. Pabbaraju Development and validation of reverse transcriptase-PCR assays for the testing of SARS-cov-2. JAMMI 2020 [View Article]
     [Google Scholar]
  7. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E et al. Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr 2021; 9:e0031521 [View Article]
     [Google Scholar]
  8. Stokes W, Berenger BM, Singh T, Adeghe I, Schneider A et al. Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19. J Med Microbiol 2021; 70:34309503 [View Article] [PubMed]
     [Google Scholar]
  9. Stokes W, Kanji JN, Hu J, Zelyas N, Berenger BM. Wide variation in threshold cycle values clouds the interpretation of SARS-CoV-2 infectiousness. Clin Chem 2021; 68:253–255 [View Article]
     [Google Scholar]
  10. Peacock WF, Soto-Ruiz KM, House SL, Cannon CM, Headden G et al. Utility of COVID-19 antigen testing in the emergency department. J Am Coll Emerg Physicians Open 2022; 3:e12605 [View Article]
     [Google Scholar]
  11. Hay JA, Kissler SM, Fauver JR et al. Viral dynamics and duration of PCR positivity of the SARS-cov-2 omicron variant. medRxiv 2022 [View Article]
     [Google Scholar]
  12. Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C et al. Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. medRxiv 2022 [View Article]
     [Google Scholar]
  13. Marais G, Hsiao N, Iranzadeh A, Doolabh D, Enoch A et al. Saliva swabs are the preferred sample for Omicron detection. medRxiv 2021 [View Article]
     [Google Scholar]
  14. Adamson B, Sikka R, Wyllie AL, Premsrirut P. Discordant SARS-CoV-2 PCR and rapid antigen test results when infectious: A December 2021 occupational case series. medRxiv 2022 [View Article]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001669
Loading
Evaluation of the ID NOW among symptomatic individuals during the Omicron wave
J. Med. Microbiol. 72, 001669 (2023); https://doi.org/10.1099/jmm.0.001669
/content/journal/jmm/10.1099/jmm.0.001669
/content/journal/jmm/10.1099/jmm.0.001669
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error